The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

She joins a team of experts at ON Partners, including partners Nina McMaster and Suzanne Zebedee, Ph.D., both recognized for ...

Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani, of T cell engagers ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Nearly 30% of the funding poured into healthcare startups last year, including for biotechs, went to companies leveraging ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...